FLGT News and Press, Fulgent Genetics Inc. From 11/07/22

Revenue totals $105.7 million Core Revenue grows 110% year-over-year to $56.0 million Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that members of it...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will relea...

Summary We are bullish on the at-home testing healthcare market but bearish for retail value investors on Fulgent Genetics until growth and momentum improve. They reported revenue growth and profits, hold a lot of cash, but face a year of possible slowing revenue and significantly...

Image source: The Motley Fool. Fulgent Genetics, Inc. (NASDAQ: FLGT) Q2 2022 Earnings Call Aug 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Fulgent Genetics, Inc. (FLGT) Q2 2022 Earnings Call Transcript

Fulgent Genetics (NASDAQ: FLGT) was one of the first companies to develop a PCR COVID-19 test and it has been highly lucrative. In this segment of "Backstage Pass" on Motley Fool Live , recorded on July 27 , Fool.com contributors Matt Frankel and Jason Hall discuss some of t...

Fulgent Genetics, Inc. (FLGT) Q2 2022 Results Earnings Conference Call August 4, 2022, 04:30 PM ET Company Participants Nicole Borsje - Investor Relations, The Blueshirt Group Ming Hsieh - Chairman and Chief Executive Officer Brandon Perthuis - Chief Commercial O...

Fulgent Genetics press release ( NASDAQ: FLGT ): Q2 Non-GAAP EPS of $0.78. Revenue of $125.34M. Outlook: Raises full year core revenue outlook to $185 million from previously announced $180 million. Total Revenue of approximately $665 million. Consensus Re...

Revenue totals $125.3 million Core Revenue grows 102% year-over-year to $45.3 million Raises full year core revenue outlook to $185 million from previously announced $180 million Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of two therapeutic industry veterans to its board of directors. Dr. Michael Nohaile, Chief Scientific Officer of Generate Biomedi...